Independent fund research. Built on SEC filings.

How we research funds

ETF · Technology Sector · First Trust

First Trust NYSE Arca Biotechnology Index Fund (FBT)

Ticker FBT · Index fund · Since 2006-06-19 · · Holdings as of Jun 30, 2026

Expense ratio
0.55%$55/yr per $10k
5-yr return
+4.3%annualized
1-yr return
+24.1%as of Dec 2025
Net assets
$2.8Ball share classes
Holdings
32

Bottom line

Is FBT a good fund? The bottom line

FBT is an index technology sector ETF from First Trust.

Its expense ratio is 0.55% — about $55 a year on every $10,000 invested, cheaper than 74% of technology sector funds we track.

It returned +24.1% over one year, +4.3% a year over five years, +6.3% a year over ten (as of Dec 31, 2025, per its prospectus).

With $2.8 billion in net assets and 32 holdings, its largest position is Corcept Therapeutics Inc (5.6%) and the top 10 make up 43.2% of the portfolio.

Updated Nov 19, 2026

What FBT invests in

The First Trust NYSE Arca Biotechnology Index Fund (the Fund ) seeks investment results that correspond generally to the price and yield (before the Funds fees and expenses) of an equity index called the NYSE Arca Biotechnology Index (the Index ).

The Fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the Index. The Fund, using an indexing investment approach, attempts to replicate, before fees and expenses, the performance of the Index. The Index is developed, maintained and sponsored by ICE Data Indices, LLC (the Index Provider ). The Index Provider reserves the right to, at any time, change the number of stocks comprising the Index by adding or deleting one or more stocks, or replacing one or more stocks contained in the Index with one or more substitute stocks of its choice, if in the Index Provider's discretion such addition, deletion or substitution is necessary or appropriate to maintain the quality and/or character of the Index. The Index is a rules-based, equal-weighted equity benchmark designed to track the performance of 30 leading biotechnology…

From the fund's prospectus (filed Apr 30, 2026).

FBT performance

Fund calendar-year total returns, 2016–2025 2016: −19.6%; 2017: +37.0%; 2018: −0.2%; 2019: +19.8%; 2020: +12.9%; 2021: −3.6%; 2022: −4.6%; 2023: +2.3%; 2024: +5.8%; 2025: +24.1% −20% 2016 +37% 2017 −0% 2018 +20% 2019 +13% 2020 −4% 2021 −5% 2022 +2% 2023 +6% 2024 +24% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
FBT+24.1%+4.3%+6.3%
Technology Sector median+24.0%+10.0%+16.7%

Source: Fund prospectus, as of Dec 31, 2025

Full FBT performance history →

What FBT costs

On a $10,000 investment, FBT's 0.55% expense ratio costs about $55 a year. The median technology sector fund charges 0.75%.

See the full FBT fee table →

FBT top 10 holdings

#Holding% of fund
1Corcept Therapeutics Inc CORT5.60%
2Neogenomics Inc NEO5.12%
3Veracyte Inc VCYT5.10%
4Bruker Corp BRKR4.32%
5Alkermes Plc ALKS4.24%
6Illumina Inc ILMN3.92%
7Krystal Biotech Inc KRYS3.87%
8Natera Inc NTRA3.79%
9Axsome Therapeutics Inc AXSM3.71%
10Neurocrine Biosciences Inc NBIX3.53%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 43.2% of the fund. See all top 25 holdings and asset mix →

Alternatives to FBT

More funds like FBT →

FBT FAQ

What is the expense ratio of FBT?
FBT's expense ratio is 0.55%, which works out to about $55 a year for every $10,000 invested.
Is FBT a good investment?
It depends on your goals, but the data points to: a typical fund for its category. This is general information, not personalized advice.
What does FBT hold?
FBT's largest holdings are Corcept Therapeutics Inc (5.6%), Neogenomics Inc (5.1%), Veracyte Inc (5.1%), Bruker Corp (4.3%), Alkermes Plc (4.2%). It holds 32 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is FBT's 5-year return?
FBT returned +4.3% a year over the five years ending Dec 31, 2025, and +6.3% a year over ten years. Past performance does not guarantee future results.
Who manages FBT?
FBT is offered by First Trust through First Trust Exchange-traded Fund.